Wida

Quick links to important sections

Wida

Method of action: Detoxifying, Hydrating

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wida

Quick Facts:

Property Description
Active ingredient Dextrose (D-Glucose)
Form Solution (Intravenous/Oral)
Pharmacological class Caloric agent, Fluid and electrolyte replenisher
General purpose Energy and volume support
Origin Natural (derived Monosaccharide)

Wida: Definition and Pharmacological Class

Wida is a pharmaceutical preparation classified primarily as a Fluid and electrolyte replenisher and a Caloric agent, designed to provide the body with essential energy and hydration. The active substance in Wida is Dextrose, which is chemically identical to D-Glucose, the fundamental Monosaccharide that fuels human cells. This classification corresponds to its role in maintaining metabolic stability. Dextrose solutions are used for the parenteral replenishment of fluid and minimal carbohydrate calories as required by a patient’s clinical condition. The medication helps restore lost water volume while also providing a simple, immediate Energy source.


Composition, Origin, and Available Forms

The active substance Dextrose is a Simple Sugar and an Essential nutrient derived from natural sources, such as starch, for pharmaceutical manufacturing. Wida, as a specific brand preparation, is primarily known for its formulation as a Sterile solution designed for rapid Parenteral administration (Intravenous solution), suitable for clinical settings where quick volume replacement and caloric support are necessary. Dextrose, USP is chemically designated D-Glucose monohydrate and is a hexose sugar. The preparation is characterized as a Single active component product, utilizing purified Water as the base and vehicle to ensure compatibility with the body's natural fluids and facilitate its roles in Hydration and Osmotic pressure regulation.


General Purpose and High-Level Action

The general purpose of a Dextrose-based medicine like Wida is to sustain the body by rapidly supplying an Energy source and volume. This Carbohydrate source and nutritional supplement ensures that all vital organ systems, particularly the brain, receive the necessary D-Glucose to support Metabolism when oral consumption or absorption is inadequate. This action is effective because Dextrose solutions containing carbohydrate in the form of D-Glucose restore blood glucose levels and provide calories. A typical, neutral use scenario is providing fluid support to individuals unable to maintain normal fluid intake, where the preparation is used to preserve bodily functions and provide critical volume and immediate caloric input.

Regulatory References

  1. NIH DailyMed for Dextrose Indications
  2. NIH DailyMed

What side effects are possible with Wida?

Possible Side Effects and Safety Information

The official regulatory safety profile for Wida (Dextrose solution) focuses primarily on adverse reactions arising from the method of administration and the effects on metabolic and fluid balance.


Adverse Reaction Scope

Classification Area Documented Entities/Systems
Key Adverse Reaction Categories Administration site reactions; Metabolic and Nutritional Disorders.
Frequency Classification Frequency is Not Known or Not Specified for many reactions, as they often derive from post-marketing reports or are related to the administration technique.
System-Organ Classes Involved General Disorders and Administration Site Conditions; Metabolism and Nutrition Disorders; Cardiac Disorders.

Commonly Documented Adverse Reactions include localized effects such as phlebitis (vein inflammation), injection site pain, and febrile response (fever). Metabolic issues like hyperglycemia (high blood sugar) and electrolyte disturbances, such as hypokalemia (low potassium), are also officially noted.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions officially listed in regulatory documents are generally consequences of unmanaged fluid or metabolic shifts, including the risk of Hyperosmolar Hyperglycemic State (a severe metabolic condition) and Severe Fluid Overload, which can lead to complications such as pulmonary edema.

Population-Specific Safety Considerations are noted for patients with diabetes mellitus and those with cardiac or renal impairment, due to increased susceptibility to hyperglycemia and fluid overload, respectively. Close monitoring of metabolic status is an officially defined requirement throughout administration, reflecting a time-related safety pattern.

Safety-Related Restrictions or Limitations include formal contraindications for use in cases of clinically significant hyperglycemia and certain conditions that pose a high risk of worsening swelling, such as some types of intracranial hemorrhage.


The official safety information structures the risk profile by emphasizing that documented adverse events are predominantly consequences of volume, rate, or metabolic shift, rather than the intrinsic chemical properties of the glucose molecule itself. This framework dictates that the central safety requirements are the monitoring and control of the patient's fluid status and glucose levels during use.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose from Wida (Dextrose solution) results primarily from the excessive or overly rapid administration of the solution. Regulatory documents strictly define the resulting manifestations based on fluid/solute overload and severe metabolic disruption.


Documented Overdose Manifestations

Over-infusion can lead to two major clinical issues, as listed in prescribing information:

  • Fluid and Solute Overload: This includes overhydration, hypervolemia, and congested states, potentially causing pulmonary edema and peripheral edema. It also results in dilution of serum electrolyte concentrations, specifically hypokalemia and hyponatremia.
  • Severe Metabolic Effects: Excessive sugar leads to profound hyperglycemia and Hyperosmolar Hyperglycemic State, evidenced by glycosuria.

Required Emergency Actions

Regulatory authorities link these conditions to severe, life-threatening outcomes and specify the mandatory response:

Outcome Category Documented Manifestation
Neurological Risk Progression to Mental Confusion, Loss of Consciousness, Coma, and Death from unchecked hyperglycemia. Risk of Acute Hyponatremic Encephalopathy (severe brain injury) is also documented.
Required Action The infusion must be discontinued immediately, the patient evaluated, and appropriate therapeutic countermeasures instituted.

Management is symptomatic and supportive, including close monitoring of fluid balance, electrolyte concentrations, and acid-base balance. Slow infusion of insulin is specified for treating severe hyperglycemia. There is no specific antidote listed for Dextrose overdose.

Specialized monitoring is required for newborns and low birth weight infants due to increased risks, and patients with impaired renal function may experience a greater risk of toxic reactions.

Therapeutic Uses of Wida

What Wida Treats: Main Uses and Benefits

Wida (Dextrose solution) is a supportive medication used primarily to address acute metabolic and fluid imbalances, offering symptomatic relief and foundational support. Intravenous solutions containing dextrose are indicated for parenteral replenishment of fluid and minimal carbohydrate calories. The main therapeutic domains focus on restoring balance and providing essential resources.


Managing Acute Low Blood Sugar (Hypoglycemia)

This medication is generally used to help manage acute symptomatic episodes of hypoglycemia, which are rapid drops in blood glucose. It is applied when patients experience noticeable physiological strain, such as weakness, confusion, or tremors, caused by a lack of energy. This generally helps with the symptomatic burden of acute episodes, providing support that helps patients cope more steadily with difficult manifestations.

“The application is relevant for providing supportive relief during periods of acute metabolic stress.”

Wida is considered relevant in clinical settings for situations involving fluid volume depletion and dehydration, alongside inadequate caloric intake due to illness or trauma.

Quick Fact: Relief for Acute Hypoglycemia
Relevant Symptom Domain Symptoms related to systemic imbalance
Key Therapeutic Benefit Provides support that helps ease the overall symptom burden

Restoring Fluid and Nutritional Balance

Wida is considered relevant in clinical settings where supportive symptom management may be appropriate for patients experiencing fluid volume depletion and dehydration. It helps address symptom clusters that may become intense or disruptive, such as intense thirst and fatigue. This assists with maintaining functional stability by contributing to the body's essential water balance and supplying foundational carbohydrate calories.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Wida (Dextrose Solution) — Official Regulatory Information

This information describes the official population eligibility rules and restrictions for Wida, as defined in government regulatory documents.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with clinically significant hyperglycemia or an established hyperosmolar state. Patients with known hypersensitivity to dextrose or corn products. Use is also contraindicated in patients with intracranial or intraspinal hemorrhage for concentrated solutions.
Age-related eligibility rules Neonates and low birth weight infants require cautious administration and frequent glucose monitoring due to increased risk. Older adults require cautious dose selection, often reflecting a greater frequency of decreased organ function.
Condition-specific eligibility rules Patients with overt or subclinical diabetes mellitus or impaired renal function must use the medicine with caution. Caution is also required for patients at risk of fluid and/or solute overload or those with severe malnutrition.
Pregnancy and lactation eligibility status Pregnancy Category C; use should be considered only if clearly needed. Caution is advised for nursing mothers as it is not known whether dextrose is excreted in human milk.

Eligibility Classifications (High-Level)

Category Classification Details
Eligibility severity classification Contraindicated: Absolute prohibition (e.g., Hypersensitivity, Severe Hyperglycemia). Use with Caution: Requires close monitoring (e.g., Diabetes, Renal Impairment).

Connection to the overall eligibility profile: Regulatory documents define eligibility through strict contraindications that prohibit use for patients with high blood sugar or known allergies to dextrose. For other groups, such as those with impaired kidney function or metabolic disorders, eligibility is conditional, requiring cautious administration as detailed in the official product labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Wida (Dextrose solution) describes interactions primarily related to administration restrictions and pharmacodynamic effects on fluid and electrolyte balance. The labeling does not document classic pharmacokinetic interactions such as those mediated by CYP enzymes or transporters.

Pharmacodynamic and Metabolic Interactions

Co-administration with certain medicinal products increases the risk of electrolyte disturbances. Drugs that increase the effect of vasopressin (e.g., non-steroidal anti-inflammatory drugs [NSAIDs], selective serotonin reuptake inhibitors [SSRIs], and Vasopressin analogues like Oxytocin) are noted to raise the risk of dilutional hyponatremia due to an additive effect on fluid retention. Similarly, combining Dextrose with Diuretics may increase the severity of electrolyte deficits. The metabolic interaction with Insulin may lead to hypophosphatemia, a consideration documented in regulatory sources.

Administration Restrictions and Incompatibilities

The label mandates strict rules for co-administration. Dextrose solution must not be administered simultaneously through the same administration set with blood products (such as whole blood or red blood cells) because of the risk of physical incompatibility, which can cause pseudoagglutination or hemolysis. When used as a vehicle for other medicines, the compatibility of the final mixture must be confirmed before mixing, and the solution must be visually inspected for precipitation or cloudiness during administration.

Interaction-Related Cautions

A restriction exists for patients with a known allergy to corn or corn products, as Dextrose is commonly derived from this source material. Furthermore, official labeling advises caution when co-administering Dextrose with Oxytocin during labour due to a specific, documented risk of maternal hyponatremia.

Mechanism of Action

The drug Wida is a triple-combination medication whose components exert distinct pharmacodynamic actions across three major mechanistic domains, resulting in convergent pathway modulation.

Angiotensin II Receptor Blockade

One component acts as a selective antagonist, engaging mechanisms that block the angiotensin II type 1 (AT1) receptor. This interaction suppresses downstream signaling sequences, reducing overall pathway activity within the renin-angiotensin-aldosterone system by limiting vasoconstrictive and aldosterone-releasing effects.

Vascular Calcium Channel Modulation

Another component modifies transmembrane ion flux, inhibiting the influx of calcium ions (Ca^2+) into vascular smooth muscle cells. This inhibition of the early molecular step of excitation-contraction coupling leads to direct peripheral arterial vasodilation, altering systemic hemodynamic parameters.

Renal Ion Transport Regulation

The third component engages mechanisms within the renal tubules by inhibiting the reabsorption of sodium and chloride ions. This effect on ion transport increases diuresis and natriuresis, resulting in a reduction in circulating volume.

Dosage and Administration Information

The Wida assessment suite (e.g., ACCESS for ELLs, WIDA Screener) is a system for measuring the English language proficiency of students in Grades K–12. Its use is governed by education agencies and requires strict adherence to administration protocols.

Administration Scope

Classification Guideline
Route of Administration Educational Assessment (Online or Paper).
Dosing Schedule/Frequency Annual (for ACCESS for ELLs) or As-needed (for Screeners), administered within a state-specific testing window.
Timing Constraints Must be administered during the defined state testing window, generally a multi-week period in the winter/spring. Individual test session times are fixed by domain (e.g., up to 85 minutes for the WIDA Screener Paper).

Procedural Requirements

Preparation Steps: Test Administrators must complete the required training course and pass the embedded quiz to obtain certification for the specific assessment being administered (e.g., Online, Paper, or Alternate). Annual recertification may be required for certain assessments. Technology coordinators must ensure devices and networks meet supported system requirements before testing begins.

Age-Group Rules: Administration is structured by grade-level clusters, which dictates the specific test form used. Assessments like Kindergarten ACCESS are administered individually, one-on-one, while other domains may be administered in a group setting, provided strict spacing and security rules are maintained.

Procedural Constraints: The Test Administrator must follow the Test Administrator Script exactly and maintain the required Security Log for the testing room. Test Administrators must not be related to any student being tested. The overall protocol requires adherence to a multi-stage process—including training, material preparation, student registration in the WIDA Assessment Management System (AMS), administration, and secure scoring—to ensure compliance for English Learner assessment.

Recent Clinical Evidence

Wida: Recent Clinical Evidence

Wida (Dextrose) has been studied for many years. The official research evidence and peer-reviewed studies explore how physiological balances are managed across various clinical indications. The evidence gathered helps contextualize outcomes measured during study periods.


Evidence for Acute Low Blood Sugar and Fluid Support

Research has focused on the immediate effects of Wida in individuals experiencing a sudden drop in blood glucose. Studies reported that administration was associated with an observed change in blood glucose levels, which research explored for its association with the resolution of acute symptoms. However, research on the optimal infusion protocols for all individuals is still uncertain, as studies noted that rapid administration may lead to subsequent blood sugar fluctuations.

Wida has also been studied for its role in supporting hydration and providing minimal carbohydrate calories. Studies examined whether the inclusion of dextrose was associated with changes in ketone levels during dehydration. Evidence is limited concerning the clinical significance of adding Wida for simple volume correction; research on the outcomes of comparative fluid types exists separately.


Research Gaps and Subgroup Evidence

Studies have explored specific administration protocols for children, neonates, and older adult populations. Findings indicate that a more measured approach to fluid administration was associated with observed differences in blood glucose variability in some studies. For older adult populations, studies note that pre-existing conditions and kidney or liver function were associated with differences in the study protocols for the solution.

Long-term effects for single, acute administration events are not fully established, as follow-up durations were limited. For prolonged use in nutritional support, research describes that long-term use was observed in some studies to coincide with changes monitored related to liver function. Research is ongoing to better define the optimal protocols, as results apply only to the populations studied.

Key Studies & References

  1. Dextrose Injection, USP label information (Caloric Agent, Fluid Replenisher)

Frequently Asked Questions (FAQ)

Common questions about Wida (FAQ)


Q: Is Wida a type of antibiotic?

Official regulatory sources classify Wida (Dextrose) as a Fluid and electrolyte replenisher and a Caloric agent. It is designed to provide energy and hydration. Wida is not classified as an antibiotic drug.


Q: Can I stop taking Wida suddenly if I feel better?

Regulatory documents indicate that when highly concentrated dextrose solutions are abruptly withdrawn, there is a possibility of a metabolic shift described as reactive hypoglycemia (a sudden drop in blood sugar). Due to this possibility, regulatory documents state that changes to administration rate or cessation should be carefully managed.


Q: How long does Wida stay in your system?

Official information describes that Dextrose is a simple sugar that is rapidly absorbed and metabolized (broken down) by the body's tissues for energy. For acute administration, the substance is processed quickly, meaning its immediate presence in the bloodstream is generally short-lived.


Q: What are the signs of a serious or rare side effect from Wida?

Serious adverse outcomes listed in official documents are generally consequences of unmanaged fluid or metabolic shifts, not the intrinsic chemical property of the drug. Official documents describe serious outcomes, which may be associated with symptoms related to Hyperosmolar Hyperglycemic State (a severe high blood sugar condition, potentially causing mental confusion) or signs of Severe Fluid Overload such as sudden difficulty breathing.


Q: What are the storage guidelines for Wida?

Official instructions state that Wida (Dextrose Solution) should be stored at Controlled Room Temperature (about 20 C to 25 C), protected from freezing and excessive heat. Official instructions indicate that, as a single-dose container, any unused portion should be discarded immediately after use.


Q: Are there specific instructions for disposing of unused Wida?

Official regulatory information mandates that the disposal of unused or expired solution must follow established local or institutional procedures for pharmaceutical waste. This ensures safe and compliant handling of medical products once they are no longer needed.


Q: Does Wida work by blocking or stimulating something in the body?

The mechanism of action for Wida (Dextrose) is not based on blocking or stimulating receptors, unlike many other drug classes. Instead, its function is primarily to act as a readily available energy source for the body's cells and to provide water for hydration.


Q: How quickly does Wida start working after taking it?

When Wida (Dextrose) is used in a clinical setting for the rapid treatment of acute low blood sugar (hypoglycemia), the onset of its effects is generally described in official sources as being rapid following intravenous administration.


Q: Does Wida make you feel sleepy or tired?

The official safety profile does not directly list sleepiness or common tiredness as primary adverse effects. However, imbalances, such as severe hyponatremia, are noted and may be associated with symptoms like lethargy or mental confusion.


Q: Why do some people need to take Wida for a long time?

Official regulatory documents indicate Wida (Dextrose solution) is used as a source of calories for patients requiring parenteral nutrition (feeding through a vein). This is required when a patient cannot receive adequate nutrition through eating or other means, which can necessitate continuous, long-term administration.


Q: Can Wida be taken with blood pressure medication?

While specific drug-to-drug interactions are not fully detailed, official documentation advises caution for patients at risk of fluid overload or with cardiac impairment (often treated with blood pressure medications). Caution is specifically advised when co-administering with diuretics due to the risk of electrolyte deficits.


Q: Can Wida affect fertility in men or women?

Official regulatory studies with Dextrose and Sodium Chloride Injections USP have not been performed to evaluate potential effects on fertility in men or women. This information is noted in the section covering use in specific populations.


Q: What official health bodies have approved Wida?

Wida (Dextrose Solution) was initially approved in the U.S. in 1940 by the relevant authorities. Authorization and oversight for the medicine are managed by governmental regulatory bodies like the FDA, EMA, TGA, and Health Canada in their respective regions.


Q: Does Wida need to be taken with food or on an empty stomach?

Wida (Dextrose Solution) is primarily designed to be administered as an intravenous infusion (through a vein) or sometimes as an oral solution. Therefore, the common instruction of taking a medicine 'with food' or 'on an empty stomach' typically does not apply to this preparation.


Q: How often is Wida typically taken?

The frequency of use depends entirely on the clinical condition being managed. Official documentation supports administration as a single, acute use (e.g., for low blood sugar) or as a prolonged, continuous infusion over days or weeks (e.g., as part of nutritional support).


Q: Can Wida cause weight gain or loss?

As Dextrose provides a source of calories (energy), it contributes to the body's total caloric intake. However, official warnings emphasize the risk of Severe Fluid Overload, which can lead to temporary increases in body mass associated with fluid retention, or edema.


Q: Does Wida change the way other medications are absorbed?

Official labeling for Dextrose solution focuses primarily on interactions that cause fluid and electrolyte shifts. The documents explicitly state that they do not document classic pharmacokinetic interactions, such as those that would typically alter how other medicines are absorbed or metabolized (broken down).


Q: Can Wida affect my ability to drive or operate machinery?

Official documents do not directly instruct on driving. However, the risk of severe metabolic imbalances, like the onset of Hyperosmolar Hyperglycemic State, is noted. Symptoms such as mental confusion would be expected to impair the ability to safely perform complex tasks.


Q: Is it normal for the color of the Wida tablet to vary?

Wida is supplied as a sterile solution in a container, not as a solid tablet. Official instructions state that the solution should not be used if it appears discolored or cloudy, or if the container's seals are not intact.


Q: Are there known reports of Wida overdose symptoms?

Official regulatory documents warn that administering Dextrose at a rate exceeding the body's ability to utilize it can lead to severe adverse outcomes. These include symptoms like unmanaged hyperglycemia, which could progress to coma, and conditions related to fluid and/or solute overloading, such as pulmonary edema.


Q: Can Wida cause issues with vision?

Official lists of adverse reactions do not commonly or directly include vision issues. However, the serious metabolic condition known as hyperglycemia (high blood sugar), which is a known adverse reaction associated with Dextrose, can have blurry vision as a related symptom.

How should Wida be stored and disposed of?

Official Storage and Disposal Instructions

The storage of Wida (Dextrose Solution) must strictly adhere to the conditions outlined in regulatory labeling to maintain its sterility and stability.

Storage Requirement Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Protect from freezing and avoid excessive heat.
Container Integrity Do not use if the solution is discolored, cloudy, or the container seals are not intact.
Stability Rule Product is a single-dose container; any unused portion must be discarded immediately.

Disposal of unused or expired solution must be managed according to established local or institutional procedures for pharmaceutical waste. If Wida is used to create an admixture with other drugs, the resulting solution is not stable for storage and must be used promptly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Wida found in:

A-Z Index: